Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GLUT5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Complex Membrane) | GLUT5/SLC2A5 Lentivirus Premade Particles Full-length human SLC2A5 ORF for stable cell line generation. Sequence Verified. |
View GLUT5 Products |
| Benchmark Ab | Anti-GLUT5 Recombinant Antibody Sequence-verified positive control for FACS, IHC, and functional blocking. |
View GLUT5 Products |
| Validator | GLUT5/SLC2A5 siRNA Set Target-specific knockdown pool for functional validation. |
View GLUT5 Products |
| Counter-Screening Target | GLUT1/SLC2A1 Lentivirus / Recombinant Protein Essential for off-target selectivity screening (glucose vs. fructose transport). |
View GLUT1 Products |
| Downstream Target | KHK (Ketohexokinase) Recombinant Protein First committed enzyme in fructose metabolism, synergistic therapeutic target. |
View KHK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 12-Pass Transmembrane Conformation Loss | Lentivirus-mediated full-length expression preserves native folding in live mammalian cells. |
| Off-Target Screening (GLUT1-4 homology) | Sequence-verified GLUT family panel available for rigorous counter-screening. |
| Lack of Verified Controls | Sequence-matched clinical benchmark antibodies and high-knockdown efficiency siRNA included. |
| False Positive Phenotypes | Dual-validation using siRNA knockdown alongside small molecule inhibition. |
Live GLUT5/SLC2A5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GLUT5 (SLC2A5) is experiencing a renaissance driven by a deeper understanding of cancer metabolism and metabolic syndromes. Historically overlooked in favor of glucose transporters, GLUT5 is a highly specific fructose transporter. Its overexpression is strongly correlated with tumor progression, metastasis, and poor prognosis in colorectal cancer, breast cancer, and acute myeloid leukemia (AML), where tumor cells metabolically reprogram to utilize dietary fructose.
The race for GLUT5 therapeutics is intensifying, with major players shifting focus from traditional non-specific hexose inhibitors to highly selective small molecules and antibody-drug conjugates (ADCs). As first-generation dietary interventions show limitations, the next wave of R&D is targeting the complete shutdown of the fructose-tumor feeding axis through selective GLUT5 inhibition, either as monotherapy or in combination with downstream pathway inhibitors like KHK blockers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Colorectal Cancer, NAFLD, Breast Cancer | Fructose uptake assays using stable overexpressing cell lines (Need Lentivirus) |
| Antibody-Drug Conjugates (ADC) | Biopharma Innovators | Solid Tumors (Breast, Colon) | Internalization assays and cell-surface density profiling (Need FACS-grade Antibodies) |
| Combination Therapies | Oncology Research Institutes | Metastatic Glioma, AML | Synergy validation with downstream metabolic enzymes (Need KHK Recombinant Proteins) |